Quick Answer
AIM ImmunoTech Inc. reported Operating Income of -$11.66 million for fiscal year 2025.
AIM ImmunoTech Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$11.66M | +41.0% |
| 2024 | -$19.77M | +38.0% |
| 2023 | -$31.92M | -60.2% |
| 2022 | -$19.92M | -5.8% |
| 2021 | -$18.84M | -24.3% |
| 2020 | -$15.15M | -21.8% |
| 2019 | -$12.44M | -8.2% |
| 2018 | -$11.50M | -0.7% |
| 2017 | -$11.42M | +17.3% |
| 2016 | -$13.80M | +17.1% |
| 2015 | -$16.65M | +12.8% |
| 2014 | -$19.10M | -11.3% |
| 2013 | -$17.17M | +15.6% |
| 2012 | -$20.34M | -42.3% |
| 2011 | -$14.29M | +12.8% |
| 2010 | -$16.39M | -23.5% |
| 2009 | -$13.26M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.45M | +45.5% | +7.5% |
| June 30, 2025 | -$2.65M | +28.4% | +26.9% |
| March 31, 2025 | -$3.62M | +36.9% | +19.4% |
| September 30, 2024 | -$4.49M | +45.0% | -21.5% |
| June 30, 2024 | -$3.69M | +32.4% | +35.6% |
| March 31, 2024 | -$5.73M | -33.5% | +29.7% |
| September 30, 2023 | -$8.16M | -25.1% | -49.4% |
| June 30, 2023 | -$5.46M | -16.3% | -27.1% |
- AIM ImmunoTech Inc. showed an increase of +41.0% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, AIM ImmunoTech Inc.’s operating income has grown by 12.1% (from -$13.26 million to -$11.66 million).
- The most recent figure is from AIM ImmunoTech Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: